Moderna Stock - FDA briefing lifts sentiment ahead of flu vaccine review

Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 20:32 CET. Details in the imprint.

Moderna (US60770K1034) is back on traders' screens after a strong move this week. The stock reacted to supportive FDA briefing documents for its experimental mRNA flu vaccine and updates to its operating model, as several market overviews highlighted on Thursday.

FDA briefing boosts Moderna

In a US market morning update on Thursday, Moderna was singled out as a top mover after supportive FDA briefing documents for its mRNA-based flu vaccine candidate and changes to its future vaccine operating model were flagged as key drivers.

The same update noted that Moderna shares jumped around 11.6% in the session, underscoring how sensitive the stock remains to regulatory signals and confidence in its non-COVID vaccine pipeline.

What the chart is signaling

Technically, the picture has brightened. Recent price data show Moderna stock trading in the mid-$50s region on Nasdaq, with a last indicated level around $55.27, while several short and medium-term moving averages now point to positive momentum.

On one technical dashboard, key moving averages from 5-day through 50-day all flash "buy" signals, and short-term pivot points cluster in the mid-$55 range, suggesting the market is testing a new trading band after this week’s move.

The product behind the stock

Moderna makes money by developing and commercializing messenger RNA-based medicines, led by its COVID-19 vaccine Spikevax and a growing pipeline in respiratory vaccines like an investigational flu shot, as well as programs in oncology and rare diseases.

Where the stock trades today

Moderna shares (US60770K1034) trade on Nasdaq at $55.27 as of 06/18/2026, 18:15 UTC.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.